Dr. Reddy’s Lab Formulation Facility Obtains Two Observations

0


The United States Food and Drug Administration (USFDA) issued Form 483 with two observations after an inspection at Dr. Reddy’s Laboratories FTO 11 formulation manufacturing plant in Srikakulam, Andhra Pradesh.

The pharmaceutical major said it would respond to submissions within the timeframe. The pre-approval inspection (PAI) took place from June 30, 2022 to July 7, 2022.

Dr. Reddy’s laboratories are engaged in the supply of medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI) and Proprietary Products.

The big pharma’s consolidated net profit fell by 82.6% to Rs 97 crore on a 15% rise in operating income to Rs 5,436.80 crore in Q4 FY22 from Q4 FY21.

Shares of Dr Reddy Laboratories fell 0.03% to Rs 4,337.25 on BSE.

Powered by Capital Market – Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear reader,

Business Standard has always endeavored to provide up-to-date information and commentary on developments that matter to you and that have wider political and economic implications for the country and the world. Your constant encouragement and feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these challenging times stemming from Covid-19, we remain committed to keeping you informed and updated with credible news, authoritative opinions and incisive commentary on relevant topical issues.
However, we have a request.

As we battle the economic impact of the pandemic, we need your support even more so that we can continue to bring you more great content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of bringing you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism we are committed to.

Support quality journalism and subscribe to Business Standard.

digital editor

Share.

Comments are closed.